; and (viii) regulatory science activities related to monograph drugs; (B) inspections related to monograph drugs; (C) monitoring of clinical and other research conducted in connection with monograph drugs; (D) safety activities with respect to monograph drugs, including— (i) collecting, developing, and reviewing safety information on monograph drugs, including adverse event reports; (ii) developing and using improved adverse event data-collection systems, including information technology systems; and (iii) developing and using improved analytical tools to assess potential safety risks, including access to external databases; and (E) other activities necessary for implementation of section 505G. (7) (A) The term monograph drug facility means a foreign or domestic business or other entity— (i) that is under one management, either direct or indirect; (ii) at one geographic location or address engaged in manufacturing or processing a monograph drug in finished dosage form; (iii) includes a finished dosage form manufacturer facility or an affiliate thereof in a contractual relationship with a monograph drug requestor or requestors to manufacture or process monograph drugs; and (iv) does not include a business or other entity whose only manufacturing or processing activities relate to— (I) production of clinical research supplies; (II) testing; or (III) packaging of packaged final dosages in a manner that does not affect the drug. (B) For purposes of subparagraph (A), separate buildings or locations within close proximity are considered to be at 1 geographic location or address if the activities conducted in them are— (i) closely related to the same business enterprise; (ii) under the supervision of the same local management